{"altmetric_id":2426729,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["FerozsonsLabs"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa62b3cf058f610007f3d","authors":["Robert Dreicer, MD, MS, FACP"],"doi":"10.1056\/nejm-jw.na34644","first_seen_on":"2014-06-11T13:26:36+00:00","issns":["1533-7820"],"journal":"Journal Watch","last_mentioned_on":1402485367,"links":["http:\/\/www.jwatch.org\/na34644\/2014\/06\/10\/dose-dense-neoadjuvant-chemotherapy-bladder-cancer"],"pdf_url":"http:\/\/www.jwatch.org\/na34644\/2014\/06\/10\/dose-dense-neoadjuvant-chemotherapy-bladder-cancer.full.pdf","pubdate":"2014-06-10T00:00:00+00:00","publisher":"Journal Watch","title":"Dose-Dense Neoadjuvant Chemotherapy for Bladder Cancer","type":"article"},"altmetric_score":{"score":0.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.5},"context_for_score":null},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/FerozsonsLabs\/status\/476684297772879872","license":"datasift","citation_ids":[2426729],"posted_on":"2014-06-11T11:16:07+00:00","author":{"name":"FerozsonsLabs4Health","url":"http:\/\/www.ferozsons-labs.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3474913780\/203cc759f65c96ae83b71b2cf021b488_normal.jpeg","description":"Founded in 1956, Ferozsons is a healthcare company that takes pride in its heritage of trust and credibility.","id_on_source":"FerozsonsLabs","tweeter_id":"1326547952","geo":{"lt":null,"ln":null},"followers":1466},"tweet_id":"476684297772879872"}]}}